Paper34775465
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.
Giusti V and 14 others. Oncogenesis, 2021. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. Papers, record 34775465. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34775465
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| IG15324 | Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) | PubMed | ||
| Fundamentally Oriented Research funds | Università di Bologna (University of Bologna) | PubMed | ||
| Fundamentally Oriented Research funds | Università di Bologna (University of Bologna) | PubMed | ||
| Fundamentally Oriented Research funds | Università di Bologna (University of Bologna) | PubMed |
Source PubMed
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30207593 | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2018 | https://conductscience.org/library/papers/30207593 | PubMed |
| 2 | 25114856 | Biological subtypes of breast cancer: Prognostic and therapeutic implications. | World J Clin Oncol | 2014 | https://conductscience.org/library/papers/25114856 | PubMed |
| 3 | 20231686 | Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20231686 | PubMed |
| 4 | 27939064 | HER2-positive breast cancer. | Lancet | 2017 | https://conductscience.org/library/papers/27939064 | PubMed |
| 5 | 30911337 | HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. | Ther Adv Med Oncol | 2019 | https://conductscience.org/library/papers/30911337 | PubMed |
| 6 | 27406316 | A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. | Nat Commun | 2016 | https://conductscience.org/library/papers/27406316 | PubMed |
| 7 | 29315431 | Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. | J Natl Cancer Inst | 2018 | https://conductscience.org/library/papers/29315431 | PubMed |
| 8 | 25994018 | Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. | Genome Biol | 2015 | https://conductscience.org/library/papers/25994018 | PubMed |
| 9 | 22124109 | Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22124109 | PubMed |
| 10 | 23002281 | Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. | Ann Oncol | 2013 | https://conductscience.org/library/papers/23002281 | PubMed |
| 11 | 29631097 | HER2-positive breast cancer: Current and new therapeutic strategies. | Breast | 2018 | https://conductscience.org/library/papers/29631097 | PubMed |
| 12 | 33302999 | Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. | J Exp Clin Cancer Res | 2020 | https://conductscience.org/library/papers/33302999 | PubMed |
| 13 | 27885439 | Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. | Breast Cancer Res Treat | 2017 | https://conductscience.org/library/papers/27885439 | PubMed |
| 14 | 31559312 | Epithelial-mesenchymal plasticity-engaging stemness in an interplay of phenotypes. | Stem Cell Investig | 2019 | https://conductscience.org/library/papers/31559312 | PubMed |
| 15 | 17471238 | The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. | Oncogene | 2007 | https://conductscience.org/library/papers/17471238 | PubMed |
| 16 | 25179116 | Intratumoral heterogeneity impacts the response to anti-neu antibody therapy. | BMC Cancer | 2014 | https://conductscience.org/library/papers/25179116 | PubMed |
| 17 | 26883193 | Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy. | Oncotarget | 2016 | https://conductscience.org/library/papers/26883193 | PubMed |
| 18 | 26367328 | Alteration of gene expression in MDA-MB-453 breast cancer cell line in response to continuous exposure to Trastuzumab. | Gene | 2016 | https://conductscience.org/library/papers/26367328 | PubMed |
| 19 | 15073130 | HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15073130 | PubMed |
| 20 | 24451168 | Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. | Breast Cancer Res | 2014 | https://conductscience.org/library/papers/24451168 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39885551 | Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma. | J Transl Med | 2025 | https://conductscience.org/library/papers/39885551 | PubMed |
| 39376056 | Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer. | Ann Med | 2024 | https://conductscience.org/library/papers/39376056 | PubMed |
| 38692097 | Grainyhead-like-2, an epithelial master programmer, promotes interferon induction and suppresses breast cancer recurrence. | Mol Immunol | 2024 | https://conductscience.org/library/papers/38692097 | PubMed |
| 38553598 | Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer-a call for enhanced surveillance strategies. | NPJ Precis Oncol | 2024 | https://conductscience.org/library/papers/38553598 | PubMed |
| 38473804 | Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38473804 | PubMed |
| 38424421 | A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy. | Curr Protein Pept Sci | 2024 | https://conductscience.org/library/papers/38424421 | PubMed |
| 37792675 | Dynamic ultrasound molecular-targeted imaging of senescence in evaluation of lapatinib resistance in HER2-positive breast cancer. | Cancer Med | 2023 | https://conductscience.org/library/papers/37792675 | PubMed |
| 37629147 | Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37629147 | PubMed |
| 37345027 | Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345027 | PubMed |
| 37251931 | Targeting breast cancer stem cells directly to treat refractory breast cancer. | Front Oncol | 2023 | https://conductscience.org/library/papers/37251931 | PubMed |
| 36997583 | Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication. | Sci Rep | 2023 | https://conductscience.org/library/papers/36997583 | PubMed |
| 36586066 | The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer. | Clin Transl Oncol | 2023 | https://conductscience.org/library/papers/36586066 | PubMed |
| 36519016 | ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC. | Transl Lung Cancer Res | 2022 | https://conductscience.org/library/papers/36519016 | PubMed |
| 36309503 | LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer. | NPJ Breast Cancer | 2022 | https://conductscience.org/library/papers/36309503 | PubMed |
| 36289916 | Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. | Biomedicines | 2022 | https://conductscience.org/library/papers/36289916 | PubMed |
| 36139701 | Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36139701 | PubMed |
| 35729189 | Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo. | Sci Rep | 2022 | https://conductscience.org/library/papers/35729189 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| PDGFRB | 5159 | PubTator's text mining | https://conductscience.org/library/genes/5159 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| PTGER2 | 5732 | PubTator's text mining | https://conductscience.org/library/genes/5732 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34775465
GET https://conductscience.org/api/papers/v1/34775465/references?page=2